Publication | Closed Access

Fenofibrate reduces progression to microalbuminuria over 3 years in a placebo-controlled study in type 2 diabetes: Results from the Diabetes Atherosclerosis Intervention Study (DAIS)

Metabolic SyndromeDiabetes ManagementFenofibrate Reduces ProgressionDiabetesPharmacologyType 2Placebo-controlled StudyPharmacotherapyDiabetes MellitusMicrovascular DysfunctionMedicineAtherosclerosis